Business
Fulgent Genetics Launches New Beacon787 Expanded Carrier Screening Panel
New 787 gene panel becomes the largest panel available on Fulgent Genetics’ platform, setting a new standard for patients seeking the most comprehensive
About this update from Fulgent Genetics, Inc.
[{"type":"text","content":"\nNew 787 gene panel becomes the largest panel available on Fulgent Genetics’ platform, setting a new standard for patients seeking the most comprehensive option for carrier screening\n\n TEMPLE CITY, Calif.--(BUSINESS WIRE)--\nFulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced the immediate availability of their new Beacon787 expanded carrier screening panel. Beacon787 will include a total of 787 genes associated with autosomal recessive and X-linked conditions. Included in this panel are all of the American College of Medical Genetics and Genomics (ACMG) tier 3 genes, which ACMG published in their latest practice guideline for carrier screening, recommending that all pregnant patients and those planning a pregnancy be offered this set of genes as an equitable, pan-ethnic screening approach. The ACMG list includes genes with carrier frequency of >1/200 for autosomal recessive conditions and disease prevalence of >1/40,000 for X-linked conditions. Leveraging Fulgent’s proprietary platform and informatics, Beacon frequently excels as it relates to analytical detection rates, ability to discern pseudogenes, and reliable copy number calls.\n\n“This is an important product launch for our company and a big step forward in carrier screening,” said Brandon Perthuis, Fulgent’s Chief Commercial Officer. “With our technology platform, we can offer this complex panel while still delivering a rapid turnaround time. For clinicians and patients looking for the most comprehensive carrier test, Beacon787 is a great option. With many couples now testing in tandem, we can quickly return results on both partners, identifying scenarios of high-risk versus low-risk. We are proud to lead the way in carrier screening development and look forward to helping our patients and their providers with their reproductive testing needs.”\n\nFulgent’s optimized workflow for variants with pseudogene interference has been validated and externally published as a method for analysis of genes with pseudogene interference and/or sequence homology issues, allowing for improved testing accuracy. This method also optimizes the turnaround time and reduces the need for unnecessary confirmatory testing to identify point mut...